cd123-cd33 ccar t cells
Cell therapyexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2018 (NCT04156256)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Interleukin-3 receptor subunit alphaImmunity, passive
IL3RA immunity, passive
- Myeloid cell surface antigen CD33Immunity, passive
CD33 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04156256 | Early Phase 1 (Phase 1) | Mar 1, 2018 | iCell Gene Therapeutics, Peking University, People's Liberation Army of China |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| iCell Gene Therapeutics | For profit | 1 | 1 | 1 | 2018 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| People's Liberation Army of China | Government | 1 | 0 | 1 | 2018 |
3 organizations
Page 1 / 1